Lv2
126 积分 2022-09-15 加入
Zanidatamab: First Approval
4小时前
已完结
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial
20天前
已完结
Real-world safety profile of eculizumab: an analysis of FDA adverse event reporting system and systematic review of case reports
28天前
已完结
Safety and Efficacy of Anti–Human Epidermal Growth Factor 2 Agents in the Treatment of Biliary Tract Cancers: A Systematic Review
2个月前
已关闭
Advances in HER2-Targeted Therapies: From monoclonal antibodies to dual inhibitors developments in cancer treatment
2个月前
已完结
Real-world efficacy of zanidatamab in patients with HER2 positive advanced biliary tract cancers
2个月前
已完结
Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study
2个月前
已完结
Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study
2个月前
已完结
First-in-human HER2-targeted Bispecific Antibody KN026 for the Treatment of Patients with HER2-positive Metastatic Breast Cancer: Results from a Phase I Study
2个月前
已完结
First-in-human HER2-targeted Bispecific Antibody KN026 for the Treatment of Patients with HER2-positive Metastatic Breast Cancer: Results from a Phase I Study
2个月前
已完结
我国群体性事件的典型特征、治理问题与对策建议
2年前
已采纳
小分子靶标的核糖开关生物传感器研究进展
2年前
已采纳
皖公网安备34019202002308
